Managing Biotechnology and Healthcare Innovation Challenges and Opportunities for Startups and Small Companies

Narges Ramezani; Erfan Mohammadi

Home/Archive/arXiv

arXiv · 2311.08671

Managing Biotechnology and Healthcare Innovation Challenges and Opportunities for Startups and Small Companies

Narges Ramezani·Erfan Mohammadi

View original source ↗Read source document ↗Export metadata ↓

Abstract

The biotechnology industry poses challenges and possibilities for startups and small businesses. It is characterized by high charges and complex policies, making it difficult for such agencies to set up themselves. However, it additionally offers avenues for innovation and increase. This paper delves into powerful techniques that can be a resource in managing biotechnology innovation, which includes partnerships, highbrow assets improvement, virtual technologies, customer engagement, and government investment. These strategies are important for fulfillment in an industry that is constantly evolving. By embracing agility and area of interest focus, startups and small companies can successfully compete in this dynamic discipline.

Explore related subjects

econ.GN q-fin.EC

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Narges Ramezani, Erfan Mohammadi. 2023-12-17. Managing Biotechnology and Healthcare Innovation Challenges and Opportunities for Startups and Small Companies. https://arxiv.org/abs/2311.08671

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Access to Live AI Advice and Behavior Under Risk: An Incentivized Experiment

Generative AI has become an everyday advisor, and the systems people consult are live and interactive, not pre-scripted. We ask whether access to such a system changes behavior under risk. In an incentivized experiment (N = 158), participants made lottery choices with an optional decision aid presented as a conventional pre-written tool, a live one-shot AI, or a live interactive AI they could query, with information format held equivalent across conditions. Risk preferences are elicited via DOSE. We find no evidence that access to a live AI advisor changes risk aversion.

econ.GN↗

arXiv2026

Bricks or Cash? Externalities of Housing Upgrading in High-density Cities

We estimate housing externalities in a high-density city, exploiting the staggered rollout of Singapore's nationwide Main Upgrading Programme for public housing. Controlling for nonrandom neighborhood exposure, we find that upgrading raises treated buildings' prices by 11.5% upon completion and neighboring buildings' resale prices by about 2% within 500 meters, decaying to zero beyond. A model with distance-decaying externalities shows that in dense settings spillovers justify the distortions of in-kind provision; this advantage diminishes and reverses at lower densities. Administrative data on over 2 million residents show that upgrading disproportionately retains older incumbents, suggesting age-specific amenities as an underexplored externality channel.

econ.GN↗

arXiv2026

The Joneses Visit an Economics Lab

Existing literature offers persuasive evidence that individuals care about how their consumption compares to that of peers, and proposes a large variety of explanatory models. The present paper proposes a common framework for many of those models, and compares their ability to predict behavior in a laboratory experiment. We find evidence of Keeping up with the Joneses motivations but also find that conspicuous consumption is enhanced by Veblen motivations arising from peers' ability to observe one's own choice. Among the seven quasi-linear preference models we compare, our data are best explained by a model that contrasts envy and pride (upward vs downward comparisons) using a value function borrowed from Prospect Theory.

econ.GN↗